🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. INT230-6

    INTENSITY THERAPEUTICS, INC.

    Breast Cancer

    phase 2 small molecule active

    2 trials

  2. IO102-IO103 in combination with pembrolizumab

    IO Biotech

    Lung Cancer Non Small Cell

    phase 2 small molecule completed

    1 trial

  3. IO102-IO103, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    IO Biotech

    Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Urothelial Bladder Cancer (mUBC), Metastatic Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  4. IONIS-STAT3Rx

    IONIS PHARMACEUTICALS INC

    Advanced Cancers

    phase 2 small molecule completed

    1 trial

  5. IPILIMUMAB, NIVOLUMAB

    Ningbo Cancer Hospital

    type B3 thymoma and thymic carcinoma

    phase 2 small molecule active

    1 trial

  6. IRINOTECAN, CALCIUM LEVOFOLINATE, ivonescimab, FOLINIC ACID, OXALIPLATIN, PACLITAXEL, FLUOROURACIL

    Ningbo Cancer Hospital

    Metastatic or locally advanced irresectable (stage IV) gastric cancer (GC) or esophagogastric junction cancer (EGJC), with and without actionable biomarker (HER2/Claudin18.2)

    phase 2 small molecule active

    1 trial

  7. IRINOTECAN, FOLINIC ACID, FLUOROURACIL, DOMVANALIMAB, FLUOROURACIL, ZIMBERELIMAB

    CERO THERAPEUTICS HOLDINGS, INC.

    stomach cancer, Esophage, gastro-oesophageal junction adenocarcinoma

    phase 2 small molecule active

    1 trial

  8. ISIS 2503

    IONIS PHARMACEUTICALS INC

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  9. ISIS EIF4E Rx

    IONIS PHARMACEUTICALS INC

    Castrate-Resistant Prostate Cancer

    phase 2 small molecule completed

    1 trial

  10. ISIS EIF4E Rx

    IONIS PHARMACEUTICALS INC

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  11. Iclusig 15 mg film-coated tablets

    Ningbo Cancer Hospital

    Chronic myelogenous leukemia

    phase 2 small molecule active

    1 trial

  12. Iclusig 15 mg film-coated tablets, BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion., Imatinib TAD 400 mg επικαλυμμένα με λεπτό υμένιο δισκία

    Cardiff Oncology

    Blood cancer

    phase 2 small molecule active

    1 trial

  13. Icotinib

    The First People's Hospital of Lianyungang

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  14. Icotinib

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  15. Ifinatamab Deruxtecan, DOCETAXEL , Raludotatug Deruxtecan

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  16. Ifinatamab deruxtecan

    Daiichi Sankyo

    Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric); urothelial carcinoma (UC); ovarian cancer (OVC); cervical cancer (CC); biliary tract cancer (BTC); human epidermal growth factor 2 (HER2)-low breast cancer (BC); HER2 immunohistochemistry (IHC) 0 BC; and cutaneous melanoma)

    phase 2 small molecule active

    1 trial

  17. Ifinatamab deruxtecan

    Daiichi Sankyo

    Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC)

    phase 2 small molecule active

    1 trial

  18. Immunological Agent

    The First People's Hospital of Lianyungang

    Lung Cancer Metastatic

    phase 2 small molecule active

    1 trial

  19. Immunomodulatory DC vaccines to target prostate cancer

    Shenzhen Second People's Hospital

    Prostate Cancer Indications

    phase 2 mab active

    1 trial

  20. Imnovid 4 mg hard capsules, JAMP Pomalidomide, Pomalidomide Adalvo 3 mg hard capsules, Imnovid 1 mg hard capsules, Imnovid 4 mg hard capsules, Pomalidomide Adalvo 1 mg hard capsules, Imnovid 2 mg hard capsules, JAMP Pomalidomide, Imnovid 1 mg hard capsules, JAMP Pomalidomide, Dexamethason 4 mg JENAPHARM®, Imnovid 3 mg hard capsules, Pomalidomide Adalvo 4 mg hard capsules, Pomalidomide Adalvo 2 mg hard capsules, Dexamethason 8 mg JENAPHARM®, Isatuximab, Isatuximab, JAMP Pomalidomide, Imnovid 3 mg hard capsul

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  21. Indibulin

    Alaunos Therapeutics

    Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  22. Induction of neo-antigen specific T cells by specialized cross-presenting dendritic cells in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy, the NEODOC study

    Disc Medicine

    Ovarian cancer

    phase 2 other active

    1 trial

  23. Inetetamab

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule active

    1 trial

  24. Inflectra 100 mg powder for concentrate for solution for infusion, Inflectra 100 mg powder for concentrate for solution for infusion, AZD0171, Oleclumab, Mycophenolate Mofetil 250 mg Capsules, Inflectra 100 mg powder for concentrate for solution for infusion, CARBOPLATIN , IMFINZI 50 mg/mL concentrate for solution for infusion., volrustomig, CISPLATIN , Monalizumab, Datopotamab deruxtecan, Inflectra 100 mg powder for concentrate for solution for infusion, Rilvegostomig, Inflectra 100 mg powder for concentra

    AstraZeneca AB

    Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources